Profile: OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
24 Oct 2014
Price Change (% chg)

$0.03 (+1.36%)
Prev Close
$2.20
Open
$2.23
Day's High
$2.23
Day's Low
$2.23
Volume
6,500
Avg. Vol
34,661
52-wk High
$14.25
52-wk Low
$2.12

Search Stocks

OncoGenex Pharmaceuticals, Inc. (OncoGenex), incorporated in October 1991, is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has four product candidates in its pipeline: custirsen, OGX-427, OGX-225 and CSP-9222. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company’s product candidates custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells, and are over-produced in response to a variety of cancer treatments. Product candidate CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer and demonstrate activation of programmed cell death in pre-clinical models.

Custirsen

Custirsen is the Company’s product candidate designed to inhibit the production of clusterin, an antiapoptotic, stress-induced protein, that promotes survival of cancer cells when overexpressed in a variety of tumors. The Company’s wholly owned subsidiary, OncoGenex Technologies Inc. (OncoGenex Technologies), entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries Ltd. (Teva), for the development and global commercialization of custirsen (and related compounds targeting clusterin, excluding OGX-427 and OGX-225). On March 6, 2012, OncoGenex Technologies and Teva entered into an amendment to the Collaboration Agreement, or the Collaboration Agreement Amendment. Under the Collaboration Agreement Amendment, OncoGenex Technologies and Teva revised the clinical development plan, or Amended Clinical Development Plan, under which three Phase III clinical trials, such as SYNERGY, SATURN and non-small cell lung cancer (NSCLC) are initiated.

A Phase III clinical trial to evaluate a survival benefit for custirsen in combination with cabazitaxel treatment as second-line chemotherapy in patients with CRPC. The trial is expected to enroll approximately 630 patients. Together with Teva, it plans to initiate this Phase III clinical trial in the second half of 2012. This trial is conducted in lieu of the Phase III clinical trial, referred to as SATURN, which is designed to evaluate a durable pain palliation benefit for custirsen in combination with cabazitaxel or docetaxel as second-line chemotherapy in patients with CRPC. A Phase III clinical trial to evaluate a survival benefit for custirsen in combination with first-line chemotherapy in patients with non-small cell lung cancer (NSCLC).

OGX-427

OGX-427 is the Company’s product candidate that is designed to inhibit production of heat shock protein 27 (Hsp27), a cell-survival protein expressed in many types of cancers, including prostate, bladder, breast and non-small cell lung cancer. The Company’s OGX-427 development activities for prostate cancer include an investigator-sponsored Phase II clinical trial evaluating OGX-427 when administered with prednisone to patients with CRPC, which is enrolled 72 patients; Phase II clinical trial of OGX-427 in patients with metastatic bladder cancer, which enrolled 180 patients, and investigator-sponsored Phase I clinical trial to evaluate OGX-427 when administered directly into the bladder in patients with bladder cancer, which enrolled 36 patients.

OGX-225 and CSP-9222

OGX-225 is a product candidate in pre-clinical development that is designed to inhibit production of both Insulin Growth Factor Binding Protein-2 (IGFBP-2), and Insulin Growth Factor Binding Protein-5 (IGFBP-5). CSP-9222, which is also in pre-clinical development, is the lead compound from a family of caspase activators. These novel, small molecules have been identified as activators of programmed cell death in pre-clinical models.

Discontinued Program-SN2310

SN2310 is a novel camptothecin for treating cancer. During 2011, the Company ceased to out-license its product candidate SN2310, and also stopped further development efforts for SN2310.

Company Address

OncoGenex Pharmaceuticals Inc

1522 217TH PLACE S.E.
BOTHELL   WA   98021
P: +1425.4879500
F: +1302.6365454

Search Stocks